Sponsored by
The FDA just approved the first FET-PET imaging drug in the U.S. (Pixclara®) for patients with glioma, including adults and children 1 month and older. FET-PET has been studied extensively in Europe and is recommended as an additional diagnostic tool in clinical practice guidelines, including the NCCN Guidelines. It provides information about tumor biology that is different from conventional MRI and may be particularly helpful when a brain MRI is difficult to interpret. Studies of FET-PET have reported sensitivity of approximately 80% or higher for helping distinguish tumor progression from treatment-related changes.